It may not be news to most people familiar with the biotech industry that one company in Cambridge is developing a drug aimed at boosting the production of a muscle-building protein in order to treat patients with Duchenne muscular dystrophy.
It may come as a surprise, however, that there are two such companies — and two such proteins.
Summit Therapeutics plc (Nasdaq: SMMT) is based in the U.K., but opened a Cambridge office two years ago, just a few blocks away from its better-known colleague…
It may not be news to most people familiar with the biotech industry that one company in Cambridge is developing a drug aimed at boosting the production of a muscle-building protein in order to treat patients with Duchenne muscular dystrophy.
It may come as a surprise, however, that there are two such companies — and two such proteins.
Summit Therapeutics plc (Nasdaq: SMMT) is based in the U.K., but opened a Cambridge office two years ago, just a few blocks away from its better-known colleague…